NCT04894643 2026-03-20
PARC
EBG MedAustron GmbH
Phase NA Recruiting
Clinical Trials
11 trialsNCT02921022 2025-11-26
Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT06975644 2025-05-22
Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)
Zhejiang Provincial People's Hospital
Phase NA Not yet recruiting
NCT06853678 2025-03-03
Second-line Immunotherapy for ES-SCLC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Recruiting
NCT04047953 2023-04-05
Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
Peking University Cancer Hospital & Institute
Phase NA Recruiting
NCT05407155 2022-06-07
BETTER
Fudan University
Phase NA Unknown
NCT04017377 2020-04-28
VMAT Concurrent Cisplatin Plus Nab-paclitaxel for Local Advanced Cervical Cancer
Peking University Third Hospital
Phase NA Unknown
NCT03690323 2018-10-01
PELICAN
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase NA Unknown
NCT03443921 2018-02-23
Divestment for Artery-involved Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT02064829 2016-03-25
TRIBECA
Sorrento Therapeutics, Inc.
Phase NA Completed
NCT01442974 2013-03-13
Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer
Grupo Hospital de Madrid
Phase NA Completed